Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ON DARE's ABOUT page (https://www.darebioscience.com/about#), this part could really elevate share price if it ever gets realized:
There are benefits of working with non-profit researchers and developers. The donor community that funds research and development shares our commitment to expanding options and improving outcomes for women. Thus, there may be funding opportunities, such as grants, which are not dilutive, as well as opportunities for us to work or partner with non-profit organizations on development and distribution efforts to ensure the innovations reach women worldwide.?
What I don't understand, if Delcath needed $25 million, why wouldn't it have attempted to push up its stock price/market cap prior to posting a filing, and then shoot for all $25 million in the filing? Once the convertible was truly complete, it only eked its way up to 4 cents, in part because they had already filed the 13G (before it was even active) so investors already knew it was coming -- we just didn't know when.
Companies definitely do not need to post news of a financing until that 13G is already active.
While they may not have been able to raise all $25 million, I am sure as a 10 cent stock, they could have raised more than $4 million. It's as if Roth and they deliberately bundled this...
The reverse split happened in the process of Cerulean selling off their assets, and their ticker essentially being acquired by DARE, which had been a private company. This last financing was DARE's first as a public company; it had been using monies used from Cerulean with the drugs that Cerulean had sold to other companies.
I think it's likely their business model will have them do a financing after each time they acquire the licensing of a new product, and that they'll always raise enough money to get them to an inflection point with that drug -- should we sell it; should we take it through FDA approval, etc? -- but I really do not see reverse splits or anything like that being a concern. They have close connections with non-profits, etc, and the concern for me is less that they are spend-happy (they're not) but that they are not as profit-motivated as they could be.
Then again, their CEO has a mostly business background.
Can you explain (or provide a link) why the press release could be grounds to suspend the stock? If possible, thanks.
BTW, the one reason I had issues with lots of your posts, pre-financing, is because I did not understand how you could be supposedly be invested if you had such a pessimistic viewpoint of company.
I personally cannot understand why they could not have gotten financing for $10 million at at about 4 cents per share if there were medical companies like Athenex which actually respected the Chemostat product. Since that did not happen, I simply do not know if there is much respect for Chemostat, yet I have always had the impression you do believe in their product.
At the very least, I think one of the investors (or banks) involved in this financing will come out (either from sober analysis or self-serving interest) with a price target above $10.
Its mgmt does not seem very savvy when it comes to the market, but I get the impression they are very respected in their community and that they'll continue to get first dibs on a lot of the best women's medicines that are being worked on at non-profits...
Really, my only concern now is that the stock reverts back to being mostly illiquid. I don't think that will happen, but one never knows.
I don't know. And Not wishing ill for anyone, so will leave it at that. Best of luck.
I thought your response made some sense, but the "no later than April 2019" date should be read no differently than the previous convertible share arrangement, where the lender could buy shares at $1.50 or at the lowest trading price of the previous 3 days, etc, which is how we ended up at 2 cents.
75 million shares is nothing -- but the bill was nothing too. There are at least 1000 SKIQ routers that will be paid soon via dilution too... so until they come out with good news, hard to see where the near-term spike will come from.
$DARE was illiquid before this financing -- its first since DARE has been on NASDAQ. Now it is quite possible that $DARE will finally trade like a very low-float ticker. Having the license to the "woman's Viagra" will give it a strong push at some point, and while the non-hormonal contraceptive lacks some pizazz, it is definitely a need for the market.
Perhaps I speak more from hope than fact, but it will erupt hard at some point now, as it has a ew sort of investor now -- the ones that like to make biotechs go from way undervalued to way overvalued in the space of a few trading days.
I am down almost $2500 in $DARE since moving my Delcath shares, and I could not sleep last night. Now, on Ash Wednesday, on a Valentine's Day where I got my wife 2 burritos from McDonalds, I feel blessed. The strangeness of life.
Anyway, hope everyone catches a huge spike here, anywhere, soon.
given huge A/S, anyone know the reason why the insiders had to surrender their shares? If they believe in the company, it seems they could have done something differently in order to pay off the recent minor debts...
this is a link to the junk article where Sheen mentions the drug: http://metro.co.uk/2017/05/06/charlie-sheen-says-hiv-drugs-left-him-with-borderline-dementia-6619221/
Not yet invested here -- am cursed, so that's a good thing to all here -- but am curious if people knew that theirs is the drug mentioned by Charlie Sheen as being the lifesaver for him. He can take it without side effects, etc, whereas the others he tried all made him nauseous and ill. It was mentioned by him over a year ago, so obviously has no effect on current stock movement, but at least is a published example of the drug being celebrated.
He said he did not know the offering had already closed when he had sold his shares. They announced it closed a few minutes after they gave the pricing, didn't they?
Am surprised the stock did not drop further. I sold the majority of my shares too at opening bell yesterday, and moved it to DARE as a conservative, temporary trade -- which immediately did a financing once it sensed I was on board. Nothing worse has happened to my life, financially, than discovering the world of biotechs.
Now starting to think this may rebound far sooner than I expected.
genuine traders who do well are worth reading. People going for a home run rely too much on luck. Case in point: I made $89000 in 2016, and lost $140000 last year. I hate that I depend so much on this stock to do well. Having held on stocks like DCTH while 15 percent up, only to be 50 percent down the next day, are not learning lessons you ever want to learn.
They bought their own Athenex stock -- to be clear. I doubt they are investing in DCTH -- one should always expect the worst, I guess -- but if they or another company do invest and can validate the value fo the product, that will be great.
Athenex insiders bought heavily on 2/9; we shall see if they get a big position in DCTH.
Reviews suggested his award-winning universal remote control came 3 years too late; it would seem the router is coming on time ... though unclear whether they've been timely with SkiQ patent stuff, etc.
I do think due diligence fortunately makes one like the company more, not less, and hopefully some clarity re: the all-important financial health of the company is coming to us soon.
From Max Li's LinkedIn resume -- or, reasons to have some faith in him...
OBJECTIVE
Ambitious executive who creates strategic alliances with organization leadership to effectively align with and support key business initiatives. Builds and retains lean high performance teams as well as developing and motivating skilled professionals. An executive who excels in resolving employer challenges with innovative solutions, systems and process improvements which prove to increase efficiency, customer satisfaction, and the bottom line.
SKILL HIGHTLIGHTS
Business development, Project management, Product development, Product line expansion, Business operations, New product delivery, Budgeting expertise, Negotiations expert, Market research and analysis, Customer-oriented, Project Planning, Risk Management, Sales, Sales Analysis, Staff Development, Organizational Restructure, Bilingual speak and write (English/Mandarin-Chinese), Cultural Communications and Customer Relations.
QUALIFICATIONS:
• 20+ years full time experience in global distribution and retail business development
• Proven track record of consistent over achievement of revenue targets
• Highly effective win-win negotiator with ability to deliver profitable revenue growth
• Expertise in complex business and partnership development, such as Microsoft, Intel, AT&T and top 10 major retail companies BestBuy, Office Depot, Costco, Fry’s and others.
• Goal driven; Self-motivated; Integrity
CORE ACCOMPLISHMENTS
Provide strategic direction to the Company at the forefront of Smart Energy industry. Develop a product development plan to advance the company's smart energy mission and objectives; and to promote retail channel revenue, profitability as well as growth to the organization. In 2010 received CES (Consumer Electronic Show) Innovation Design and Engineering Award in the Home Theater Accessories Product Category for creating an advanced Universal Remote Control while working with Silver PAC, Inc. Established unyielding relationships with Microsoft, Intel, CEA/CES and others.
Hopefully a good press release next week. If they were able to make some sales of their products at the conference, or have any positive update on their product development with AT$T, it should be a good week.
The pessimism on the board (which is almost needed to balance out the pumping) largely stems from posts that are reading more into the AT&T press release than what's officially written there. Company simply has a shot at being a supplier to AT&T; if it starts feeling like they have a good shot, perhaps it will help the stock price (from which all would be grateful).
I optimistically imagine the company to be like the fictional company from "Silicon Valley" -- the only big red flag is the way they are paying off debt now, but it seems as if that's largely based on loans made before the company's better ideas have seen the light of day, and it's hopeful that is soon part of the past.
It seems you are over-asking this point, as an investor. We have yet to see anything, in terms of financials, that suggest any (current or future) partnership has fronted them with the possible millions needed for millions of customers.
Also, it does not seem prudent for the company to spend a lot of money manufacturing a product that they do not as yet have patents for... or am I overlooking something?
Post #36030 is a good post, thanks. I need to hear some honest posts here that do not make every drop appear as if people are accumulating, ready to send the stock soaring. My primary concerns about this stock have largely been its posters -- but then again, I am hoping they are successful at their pumping game.
As for your lawyer link, are you sure he is in family law? Could that be another Peabody? His first name is Timothy, so it is not an uncommon first name.
Post #36030 is a good post, thanks. I need to hear some honest posts here that do not make every drop appear as if people are accumulating, ready to send the stock soaring. My primary concerns about this stock have largely been its posters -- but then again, I am hoping they are successful at their pumping game.
As for your lawyer link, are you sure he is in family law? Could that be another Peabody? His first name is Timothy, so it is not an uncommon first name.
Serious question. Do companies typically mention the company(ies) in China/Asia where they are getting parts made, etc, for products? I know where APPLE has gotten into some trouble when it's employed some companies which hire children to help make their parts, but it's not as if, when those problems came to light, there was some sort of dramatic production stoppage... as other companies were also making the products for them. And while APPLE could likely provide a full list of all the companies they employ, would that be the norm or exception? I invest in too many low-caps to have a clue.
I have no high expectations for SkiQ. They won't be producing billions of this product. They will either partner or they will be acquired or they will not have much success. They have been obscenely diluted over otherwise small debts, and it sure would have been nice to have insiders who are still invested (that they had to surrender shares does not seem a positive, no matter how that's worded), so any concerns about funding make sense to me.
While the patent press release was piffle, the concern may be that they are already too late in the game to have done that. I would have thought or hoped that they submitted a patent for it before they started to promote it.
The surge suppressor is sold at AMAZON. I rewrote a sentence and left that important word out in my response...
SkiQ is essentially a new product. When it is ready to roll out, it seems they have the means and know-how to do that (via by itself or via partnership, etc) as the "smart" surge suppressor they invented is currently sold there. The reviews of the surge supressor range from "great" to "terrible". Aside from its high price, some of the buyer complaints make it sound as if the company needed some quality control analysts to help with bugs in the set-up process. And since there is also a much cheaper version, by a different company, getting good reviews, it is also possible they failed to successfully patent their idea.
Anyway, the surge suppressor obviously is not a big financial success right now, as the revenue from last year is small, but it was reviewed in major media (positively), and definitely made me feel okay about this stock. There is obviously an attempt to pump it on the boards, and there are lesser people trying to trash it. Check the website for their presentation on the SkiQ product that was done at CNET. That should at least make you more comfortable about whether the stock is worth/not worth investing in at a particular price.
Thanks for a post that doesn't seem to imply the stock is soaring right now.
Why would a company not put out a press release if dilution has stopped, and debt dissolved?
I stand corrected. Sincere apologies: https://www.rennovahealth.com/news-media/press-releases/detail/258/rennova-health-inc-announces-4000000-funding-from
Rennova did a $4 million equity financing in December (?) where investor gets shares at an 85 percent discount. 85 percent discount of a 1.5 cent share = a whole lot of shares. One can always make money on a short-term trade -- but it's not easy with this ticker IMO.
I assumed they were near done. Others (who I trust more, as I barely follow this) think only halfway done.
If halfway done, 2 million dollars can buy a lot of shares at current price.
.015 (shares at 1.5 cents) * .15 (85 percent discount) * 500000000 (500 million shares) = only $1,112,500
Without clarity, one needs to keep this a short-term trade.
Great post made an hour before you said you sold your 500,000 shares...
You've basically left this ticker confused, and now it's going up.
Getting an 85 percent discount at less than 1.5 cents = a lot of shares. OS is likely 200 million or more IMO. But that still gives a market cap to company that's less than the $4 million offering.
Your speculation likely as good as anyone else's. I personally assume they need to end the currently dilutive financing as quickly as possible as they just made an offer on another hospital and they need to do another financing prior to closing on it.
Last time they came out with good news, the BID was 20 percent over closing price to start the market that day. It then shot up 50 percent quickly before inevitable sell-off.
Sam has made it clear he likes Delcath, and that he also has the funds to become very opportunistic while the stock is heavily devalued. He is shooting for a one-year payoff that may be more ambitious than many of our short-term targets -- at least that's how I interpret the motivation behind his posts. He may be deliberately trying to influence people to dump their shares -- but he also is apparently not selling his shares -- and it's up to the individual investor to take his comments, or my comments, or anyone's comments, with a grain of salt or not.
I personally need this stock to go up, and so I want it to go up, and I believe the market cap valuation will allow what I need and what I want to be realized at some point. Hopefully sooner than later. With some other poorly managed biotechs (like TNXP), they have doubled before announcing their financing price. With any luck, ours will triple before that happens. Definitely there's a need to be paying attention to this stock until the pricing is formally announced.
Publication date (?) of most recent Delcath patent was on February 1, 2018: https://patents.justia.com/assignee/delcath-systems-inc
Apparatus for Removing Chemotherapy Compounds from Blood
Publication number: 20180028740
Abstract: A filter apparatus for removing small molecule chemotherapy agents from blood is provided. The filter apparatus comprises a housing with an extraction media comprised of polymer coated carbon cores. Also provided are methods of treating a subject with cancer of an organ or region comprising administering a chemotherapeutic agent to the organ or region, collecting blood laded with chemotherapeutic agent from the isolated organ, filtering the blood laden with chemotherapeutic agent to reduce the chemotherapeutic agent in the blood and returning the blood to the subject.
Type: Application
Filed: July 17, 2017
Publication date: February 1, 2018
Applicant: Delcath Systems, Inc.
Inventors: Daniel S. Johnston, Jacques Chammas, William M. Appling, Samantha J. Barton
ASk at .0369 ... finally some signs of forward movement. Hopefully a few days of this before a PR-driven move.
Warrants have not yet been priced. Nor has the financing.